Fundraising Fox
🦊/Companies
Sign in

Sensulin

2 known investors

Find your way into Sensulin

1,223 people in our graph share verified history with the Sensulin team — schools, employers, funds. One of them is your warm intro.

Tobi Cokerunlockedknows Mike Moradi · together at Kauffman Fellows (overlapped)
knows the team · via INSEAD
knows the team · via World Economic Forum
×4knows the team · via Kauffman Fellows
knows the team · via Minutia
knows the team · via National University of Singapore

Sensulin is a preclinical biopharmaceutical company developing glucose-responsive insulin therapies for type 1 and type 2 diabetes that aim to reduce hypoglycemia risk and daily injection requirements. The company's technology targets long-term complications of diabetes while potentially eliminating the need for separate basal and mealtime insulin dosing.

BiotechMedical Devices

Founders & leadership

DBDan Bradbury
Dan Bradburyin𝕏Executive Chairman and Co-FounderDan Bradbury is Executive Chairman and Co-Founder of Sensulin, a preclinical biopharmaceutical company developing glucose-responsive insulin therapies for diabetes. He has over 40 years of experience in life sciences executive roles focused on business strategy and bringing novel medicines to market.
MMMike Moradi
Mike Moradiin𝕏CEOMike Moradi is co-founder and CEO of Sensulin, a biopharmaceutical company developing glucose-responsive insulin therapies for diabetes. He brings 25 years of experience founding and leading ventures in biotech and nanotechnology, including prior roles at eyeCRO and Unidym (acquired by Wisepower), and holds a Wharton Executive Education certificate in Corporate Governance.

Board

AA
Ananth AnnapragadainFounder
CRChristopher Rhodes
Christopher RhodesinFounder

Investors · 2

BioBritLa Jolla
Cortado VenturesOklahoma City

Competitors · 4

by search overlap
Eli Lilly8 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
BiPar Sciences6 shared keywordsBiopharmaceutical developer of tumor-selective PARP inhibitor cancer therapies, acquired by Sanofi-aventis in 2009.
Diabetes5 shared keywordsA nonprofit organization that provides educational resources and information about prediabetes, including prevention strategies and lifestyle management for Americans at risk of developing type 2 diabetes.
Medscape4 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Sensulin for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase ISTTR2014$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Sensulin Raises Undisclosed Series B Funding Round - FinSMEsfinsmes.com · May 2018Innovators: Sensulin - i2Ei2e.org · Mar 2013

Frequently asked questions

What does Sensulin do?
Sensulin is a preclinical biopharmaceutical company developing glucose-responsive insulin therapies for type 1 and type 2 diabetes that aim to reduce hypoglycemia risk and daily injection requirements. The company's technology targets long-term complications of diabetes while potentially eliminating the need for separate basal and mealtime insulin dosing.
Who founded Sensulin?
Sensulin was founded by Dan Bradbury.
Who are Sensulin's investors?
Sensulin's investors include BioBrit, Cortado Ventures.